DUBLIN--(Business Wire)--
Research and
Markets(http://www.researchandmarkets.com/research/b3f479/the_pharmaceutical)
has announced the addition of the "The Pharmaceutical Market: Brazil" report to
their offering.
Due to the depreciation of Brazil's currency against the US dollar, the
Brazilian pharmaceutical market has fallen in dollar values in 2009. Controlled
drug prices are increasing below inflational levels and demand is contained by a
falling economic growth projected in 2009. For the industry, price controls are
not directly linked to consumption levels. In fact, between 1997 and 2008, the
pharmaceutical market by volume increased significantly only in 2004.
The pharmacy sector in dollar values performed exceptionally well in 2008, but
the sector is starting to register slower growth in the first quarter of 2009.
Generic medicines continue to grow at a higher rate than overall pharmacy sales,
and are expected to represent 20% of the sector by volume in 2010. Foreign
participation in the generic sector has increased following sanofi-aventis'
acquisition of Medley, recently announced in 2009.
The Chamber for the Regulation of Medicines (CMED) has authorised price
increases on nearly 18,000 drug presentations which are controlled. Annual price
adjustments are based on price ceilings which are calculated taking into account
the National Broad Consumer Index (IPCA) between March 2008 and February 2009, a
productivity factor, equal to 0.0% in 2009, and inter- and intra-sector factors.
Brazil has a history of talking tough with foreign producers. Under Decree
4,830/2003, Brazil allows compulsory licensing in cases of national emergency or
public interest; Brazil issued its first compulsory licence in May 2007, for
Merck Sharp & Dohme's Stocrin (efavirenz). Rising patient numbers, increasing
resistance levels, rising costs and high-risk behaviour are factors which will
continue to threaten HIV/AIDS patents.
Espicom's in-depth pharmaceutical market reports are ideal for executives
wanting to understand the key drivers in pharmaceutical markets and have access
to a wealth of statistical data. Each report opens with an outlook section that
provides analysis of the market, 5-year market forecasts, national data
projections, market outlook and key developments such as regulation,
pricing/reimbursement, intellectual property, health facilities and government
policy. The report also provides extensive background information, population
trends, health status, health expenditure, organisation & administration,
hospital services, medical personnel, healthcare development, market access
information, trade data for raw materials and finished products and essential
industry contacts. Included with the report are 3 free quarterly updated outlook
reports, enabling you to keep up to date with market developments for a year.
Key Topics Covered:
* Executive Summary
* Pharmaceutical Market
* Key National Data Projections
* Geography
* Political Overview
* Economic Overview
* Population
* Demographic Indicators
* Mortality
* Morbidity
* Organisation & Administration
* Health Expenditure
* Hospital Services
* Ambulatory Care
* Medical Personnel
* Regulatory Environment
* Distribution Channels
* Pharmaceutical Imports
* Domestic Production & Exports
* Directory
Companies Mentioned:
* Biosintética
* Cristália
* Boehringer Ingelheim
* Sanofi-Aventis
* Aché
* Pfizer
* Libbs
* Profarma
* Abbott
* Allergan
* Altana
* AstraZeneca
* Bayer-Schering
* Bristol-Myers Squibb
* Eli Lilly
* Farmalab Chiesi
* GlaxoSmithKline
* Merck
* Merck Sharp & Dohme Novartis
* Novo Nordisk
* Roche
* Schering Plough
* Wyeth
For more information visit
http://www.researchandmarkets.com/research/b3f479/the_pharmaceutical
Source: Espicom Business Intelligence Ltd
Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Copyright Business Wire 2009
